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Abstract: The extract from Mitragyna speciosa has been widely used as an opium 
substitute, mainly due to its morphine-like pharmacological effects. This study investigated 
the effects of M. speciosa alkaloid extract (MSE) on human recombinant cytochrome P450 
(CYP) enzyme activities using a modified Crespi method. As compared with the liquid 
chromatography-mass spectrometry method, this method has shown to be a fast and cost-
effective way to perform CYP inhibition studies. The results indicated that MSE has the 
most potent inhibitory effect on CYP3A4 and CYP2D6, with apparent half-maximal 
inhibitory concentration (IC50) values of 0.78 µg/mL and 0.636 µg/mL, respectively. In 
addition, moderate inhibition was observed for CYP1A2, with an IC50 of 39 µg/mL, and 
weak inhibition was detected for CYP2C19. The IC50 of CYP2C19 could not be 
determined, however, because inhibition was <50%. Competitive inhibition was found for 
the MSE-treated CYP2D6 inhibition assay, whereas non-competitive inhibition was shown 
in inhibition assays using CYP3A4, CYP1A2 and CYP2C19. Quinidine (CYP2D6), 
ketoconazole (CYP3A4), tranylcypromine (CYP2C19) and furafylline (CYP1A2) were 
OPEN ACCESS
Molecules 2011, 16 
 
 
7345
used as positive controls throughout the experiments. This study shows that MSE may 
contribute to an herb-drug interaction if administered concomitantly with drugs that are 
substrates for CYP3A4, CYP2D6 and CYP1A2.  
Keywords: herb-drug interactions; cytochrome P450 (CYP); Mitragyna speciosa;  
in vitro; alkaloids 
Abbreviations: MSE, Mitragyna speciosa alkaloid extract; CYP, cytochrome P450; 
AMMC, 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin; BFC, 
7-benzyloxy-4-(trifluoromethyl)-coumarin; HFC, 7-hydroxy-4-(trifluromethyl)-coumarin; 
NRS, NADPH regeneration system; CEC, 3-cyano-7-ethoxycoumarin; DMEM, 
Dulbecco’s modified Eagle medium; DMSO, dimethyl sulfoxide; G6P, glucose-6-
phosphate; G6PDH, glucose-6-phosphate dehydrogenase; NADP+ nicotinamide adenine 
dinucleotide phosphate; RFU, relative fluorescence units 
 
1. Introduction 
Mitragyna speciosa Korth is a tropical herb plant belonging to the family Rubiaeceae found mainly 
in Southeast Asian countries such as Thailand and Malaysia. It is known as “Biak-biak” or “Ketum” in 
Malaysia, and as “Kratom” in Thailand [1]. Thai and Malaysian natives traditionally consume the 
leaves by chewing, smoking or drinking them as tea, mainly for the stimulant and euphoric effect [2]. 
In human and animal studies, the leaves have been reported to possess morphine-like properties, 
including antitussive, anaesthetic, antinociceptive, analgesic and stimulative effects [3]. Since the 
nineteenth century, Kratom has been widely used as an opium substitute during opium withdrawal, as 
well as for pain relief. However, addiction and signs of opioid abstinence syndrome, such as 
irritability, yawning, rhinorrhoea, myalgias, diarrhoea, tremor, nausea, nystagmus and arthralgia, have 
also been reported [2], thereby limiting its use.  
Although the pharmacological effects of Kratom in humans and animals have been well established, 
the doses required to produce stimulation, analgesia and toxicity in humans still remain poorly defined. 
Abuse of the plant by drug addicts, however, has caused major concerns in Malaysia and Thailand, and 
consequently, the Kratom plant has been listed as a controlled item in Malaysia, Thailand and 
Australia. In other parts of the world, Kratom is currently not strictly regulated, and access to Kratom 
through the Internet has led to significant drug abuse problem among the Western population seeking 
self-treatment of opioid withdrawal and chronic pain [2,4].  
Cytochrome P450 (CYP) is the major family of enzymes involved in metabolism of drugs, toxicants 
and endogenous compounds. Metabolism is generally regarded as a protective mechanism via the 
production of inert metabolites, but it can also cause toxicity by activation of pro-drugs to active 
metabolites. Members of the CYP subfamilies exhibit relatively strict specificities in the metabolism of 
xenobiotics. The CYP1, CYP2 and CYP3 subfamilies are responsible for the metabolism of >90% of 
commercially available drugs [5]. Preliminary understanding of the metabolism of a new chemical 
entity and its affinity to certain metabolizing enzymes is helpful during drug development to avoid 
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undesirable drug-drug interactions that may lead to changes in the rate of drug metabolism and 
potentially contribute to drug toxicity [6]. For example, ketoconazole and quinidine are well-known 
CYP3A4 inhibitors that can induce life-threatening heart rhythm disorders when co-administered with 
other substrates of CYP3A4, such as erythromycin [7,8]. In 2006, the U.S. Food and Drug 
Administration drafted an industry guideline on drug interaction studies to reflect the importance of 
studying drug metabolism when assessing the safety and effectiveness of new drugs [9]. 
Many methods are available to measure enzyme activity in order to avoid pharmacokinetic  
drug-drug interaction due to CYP enzyme inhibition. These methods can be categorized according to 
the experimental system and screening strategies [10]. During the drug development process, the 
fluorescence measurement technique has the advantage of being less time-consuming and more  
cost-effective. For this method, the pro-fluorescent substrate is broken down to a fluorescent product 
by CYP enzymes and detected directly using a fluorescence plate reader. With the development of 
sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) instruments, the analysis of 
metabolite generation from unlabelled drug substrates has become more efficient and highly specific. 
However, compared with the results of the fluorescence method, the productivity of drug-drug 
interaction assessment with LC-MS/MS is relatively low. Moreover, the requisite LC-MS/MS 
instrumentation is costly.  
The objective of this study was to evaluate the effect of M. speciosa alkaloid extract (MSE) on CYP 
enzymes by using novel high throughput in vitro fluorescent P450 assays. MSE was tested for its effect 
on CYP3A4, CYP2D6, CYP1A2 and CYP2C19 to determine the potential risk for causing interactions 
with other therapeutic products.  
2. Results and Discussion 
2.1. Determination of Optimal Incubation Time 
The calibration curves were prepared at different incubation times. Optimal incubation times were 
determined when good linearity was obtained in which the r2 value approached 1.0. The optimal 
incubation time for CYP3A4, CYP2D6 and CYP2C19 was 30 min, whereas the optimal incubation 
time for CYP1A2 was 20 min. For all CYP inhibition assays, the formation of fluorescent metabolites 
was proportional to the substrate concentration and incubation time. To determine the Km and Vmax 
values, we chose the optimal incubation time obtained from the previous experiment. 
2.2. Determination of Km and Vmax Values 
The assay was designed according to the Crespi method in that Km and Vmax values were 
determined using 10 substrate concentrations generated by 3× dilutions (1–300 µM). At a substrate 
concentration above 300 µM, a precipitation was observed that affected the fluorescence measurement. 
The Km values for CYP3A4, CYP2D6, CYP1A2 and CYP2C19 were 48.94, 1.016, 23.69 and 4.627 µM, 
respectively. The Km values estimated in this study were similar to those reported by Crespi et al. [11]. 
The Vmax values for CYP3A4, CYP2D6, CYP1A2 and CYP2C19 were found to be 2,343, 47.18, 
20,307 and 2,087 RFU product/min/pmol P450, respectively. The velocity of the reaction showed a 
hyperbolic pattern and approached the maximum velocity with increasing substrate concentration. The 
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Km values of the standard inhibitor are summarized in Table 1. The substrate concentration used for the 
subsequent assay was close to the apparent Km values so that competitive inhibition could be detected 
with comparable efficiency. 
Table 1. Km and IC50 values of the standard inhibitors reported in the literature.  
a Reference from database of Aurigene Discovery Technologies, Ltd.; b Donato et al. [13]. Data were 
expressed in standard error of the mean (S.E.M). 
2.3. Determination of IC50 for Standard Inhibitors  
The IC50 values for each of the P450 enzymes were determined by using a single concentration of 
enzyme and substrate that had been optimized previously. The standard inhibitor IC50 values were then 
compared with those in the literature and with the database of Aurigene Discovery Technologies 
(Table 1). IC50 value determinations were performed with quinidine (CYP2D6), ketoconazole 
(CYP3A4), tranylcypromine (CYP2C19) and furafylline (CYP1A2) as positive controls. Quinidine, 
ketoconazole, tranylcypromine and furafylline are both specific and potent inhibitors of specific liver 
CYP enzymes [9,11,12]. The IC50 values for the standard positive inhibitors in this study were very 
close to the reference values, indicating that the condition of the in vitro system was suitable for 
subsequent pharmacokinetic studies [13]. 
2.4. Determination of IC50 for MSE 
Standard positive inhibitors and MSE were added separately to the in vitro drug-metabolizing 
systems at varying concentrations (2–10 µM for standard positive inhibitors and 0.05–100 µg/mL for 
MSE). The CYP-dependent inhibition was observed only at doses lower than 250 µg/mL MSE. High 
concentrations of MSE were found to interfere with the fluorescence measurement [1]. We found that 
MSE was a strong inhibitor of CYP3A4 and CYP2D6 with an IC50 of 0.78 µg/mL and 0.636 µg/mL, 
respectively. MSE appears to inhibit CYP1A2 moderately with an IC50 of 39 µg/mL. The IC50 of 
CYP2C19 was not determined, however, because inhibition was <50%. The results are summarized in 
Table 2 and Figure 1. 
Cytochrome/Substrate 
This study  Reference 
Km (µM) IC50 (µM)  Km (µM) a IC50 (µM) a,b 
3A4/BFC 48.94 0.045  50 0.06 ± 0.016 b 
0.09 ± 0.03 a 
2D6/AMMC 1.016 0.005  1.5 0.0069 ± 0.0006 b 
0.5 ± 0.2 a 
1A2/CEC 23.69 0.755  25 0.58 ± 0.05 b 
1.4 ± 0.3 a 
2C19/CEC 4.627 2.511  5 2 ± 0.5 b 
3.2 ± 1.2 a 
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Table 2. Summary of IC50, Ki values and inhibition mode of MSE on CYP activities.  
a Ki values are derived from secondary plots of slopes taken from double reciprocal plots 
versus MSE concentrations. The compounds were classified as potent (IC50 ≤ 20 µg/mL or 
≤10 µM); moderate (IC50 from 20 to 100 µg/mL or 10 to 50 µM) or weak (IC50 from  
≥100 µg/mL or ≥50 µM) [14]. Data are the average values of duplicate determinations;  
b Nd, not determined. 
Cytochrome P450 IC50 (µg/mL) Ki (µg/mL) Mode of inhibition 
3A4/BFC 0.78 1.526 a Non competitive 
2D6/AMMC 0.636 2.6 a Competitive 
1A2/CEC 39 18.57 a Non competitive 
2C19/CEC Nd b 84.88 a Non competitive 
Figure 1. Percentage of inhibition of MSE on (a) CYP3A4; (b) CYP1A2; (c) CYP2D6; 
and (d) CYP2C19 activities after incubating at respective optimal incubation times. Two 
different concentrations (2 µM and 0.2 µM) of positive control (quinidine [CYP2D6], 
ketoconazole [CYP3A4], tranylcypromine [CYP2C19] and furafylline [CYP1A2]) were 
used throughout the assay. 
 
2.5. Determination of Ki Values and Modes of Inhibition for MSE 
The most important measurement for a compound as an indication of its inhibitory potency is Ki, 
the inhibition constant. It is an indication of the affinity of a compound for an enzyme. Various 
concentrations of substrates were incubated with the respective CYP isoforms in the absence and 
presence of different concentrations of MSE. The Ki and modes of inhibition for MSE in different 
CYP activities are summarized in Table 2. MSE showed non-competitive inhibition for CYP3A4, 
CYP1A2 and CYP2C19, in which the apparent Km was increased, together with a decrease in Vmax. 
The reduction of the “active” enzyme results in a decrease of Vmax. However, MSE was a competitive 
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inhibitor for CYP2D6, as shown by the increasing values of Km, with Vmax remaining unchanged 
(Figure 2). The Dixon plot s/v versus concentration of MSE was plotted to differentiate the mode of 
inhibition (Figure 3). 
Since the 1980s, studies on specific forms of CYP using in vivo and in vitro systems have attracted 
the attention of researchers because of a most interesting characteristic of CYP: substrate specificity 
and inhibitor selectivity. CYP2D6 is relatively specific for metabolizing positively charged molecules 
with a basic nitrogen atom. CYP1A2, on the other hand, is involved in the metabolism of polyaromatic 
hydrocarbons, and CYP2C9 metabolizes weakly anionic molecules [15]. Most organic compounds can 
therefore be metabolized by CYP enzymes. It should be kept in mind that the kinetic characteristics of 
enzymes are important for the metabolism and clearance of drugs [12]. In this study, CYP1A2 showed 
a relatively high reaction rate compared with other CYPs, whereas CYP2D6 showed the lowest 
reaction rate; CYP3A4 and CYP2C19 had a moderate rate of reaction. There was a relatively large 
difference between the Vmax values found in this study from those reported in the literature [11,12] 
This finding may be due to different sources of human liver microsomes used such as P450 expression 
cell lines and baculovirus infected insect cells (BTI-TN-5B1-4) [10,11]. Differences in enzyme 
expression systems, including proteins, lipids, co-enzyme concentrations, ratios of reductase and 
cytochrome b5, phospholipid composition of microsomes and incubation conditions adopted in 
different laboratories, may also bring about significant changes in the Vmax and Km values [10].  
Figure 2. Ki determination using the non-linear regression method. Direct plot reaction 
velocity against different concentrations of substrate in the absence or presence of different 
concentrations of Mitragyna speciosa extract. Increasing the M. speciosa extract 
concentration resulted in reduced apparent Vmax and increased apparent Km for CYP3A4, 
CYP1A2 and CYP2C19. For CYP2D6, Vmax remained constant but the Km value was 
increased (not shown). 
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Figure 3. Dixon plot of substrate concentration/velocity (s/v) against i (M. speciosa 
extract) concentration for each of the substrate concentrations tested. The resulting  
lines intercept at a point corresponding to Ki. Each point was the mean of  
triplicate determinations. 
 
Mitragynine, reported to be the most abundant alkaloid in M. speciosa extracts [16], has some 
morphine-like properties such as antinociceptive, antitussive, antimalarial and antidiarrheal effects [17]. 
Interestingly, mitragynine is structurally different from morphine (Figure 4) yet the two produce 
similar pharmacological effects. The chemical structure of mitragynine contains an indoloquinolizidine 
moiety with a methoxy group at the C-9 position. As reported, the antinociceptive effect of the leaves 
was mediated by µ- and δ-opiate receptors which have a similar mechanism of action as morphine. 
However, the finding of Matsumoto et al. showed that 7-hydroxymitragynine has stronger antinociceptive 
effects as compared to morphine and mitragynine. The introduction of hydroxy group at the C-7 
position has been proposed to have stronger affinity to µ- and k-opiate receptor [18]. Seven 
metabolites had been identified after the Phase I metabolism hydrolysis of the methyl-ester group in 
position 16, 9 and 17; while four metabolites were found in the Phase II metabolism of mitragynine in 
human and animal [19]. Anyhow, the effects of those metabolites still remains unknown. Due to the 
unique hydrophobic properties of plant alkaloids, they easily pass through the blood brain barrier and 
affect the opiate, noradrenaline, dopamine and serotonin receptors. Other active constituents found in 
the extract, such as speciofoline, rhychophylline and stipulatine, are suspected to contribute to some 
extent to the herb-drug interaction [20]. However, the active substances of M. speciosa responsible for 
substrate metabolism in this study remain unknown, and thus underestimation of the total inhibitory 
potential of the compound may have occurred. Nonetheless, the alkaloid extract in our study may 
provide fundamental and representative data on the isoforms examined because people usually 
consume the herb as a whole leaf instead of in the form of a particular active ingredient.  
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A comparison of our results for the IC50 of MSE with those of Hanapi et al. suggests that our study 
had a similar pattern of inhibition but with a stronger inhibitory effect [6]. Our results appear to show a 
100-fold stronger inhibition for CYP3A4 and a 6-fold stronger inhibition for CYP2D6 compared with 
the results from the Hanapi et al. study [6]. On the other hand, the reported MSE-induced CYP2C19 
inhibition effect in both studies was considered low. However, the IC50 value of CYP2C19 in  
Hanapi et al. was relatively high compared with our results [6]. These findings may be due to the 
variability of working with natural products. Unlike conventional single active compounds, natural 
products are complex mixtures containing various chemical substrates that can vary as a result of 
environmental factors such as climate, growth conditions, harvest and storage conditions [6,15]. In 
addition, variations in the manner of preparation and the extraction methods can also contribute to  
data variability.  
In this study, MSE was found to be a non-competitive inhibitor for CYP3A4, CYP1A2 and 
CYP2C19, with Ki values of 1.526, 18.57 and 84.88 µg/mL, respectively. Non-competitive inhibition 
is characterized by binding of the inhibitor to the side other than the active site (allosteric site) of the 
free enzyme or of the enzyme substrate complex. The presence of the inhibitor causes a change in the 
structure of the enzyme so that it no longer binds to the substrate or catalyzes product formation. An 
increased Km value and decreased maximum enzyme reaction rate (Vmax) was observed, as shown in 
Figure 2. Non-competitive inhibition can be easily distinguished from other types of inhibition by 
identifying similar Ki values in both the 1/v against i and s/v against i graphs. In addition, another 
characteristic of non-competitive inhibition is that the intersections are found on the i axis in both 
graphs [21]. 
In competitive inhibition, the substrate competes with the inhibitor for binding to the active site of 
the enzyme. Therefore, inhibition can be overcome at sufficiently high substrate concentrations, with 
the Vmax remaining unaffected. Moreover, the condition Ki = ∞ (the lines are parallel) was found in the 
Dixon plot (s/v against i), whereas an intersection was found in the conventional Dixon plot 1/v against 
i [21]. This finding indicated that MSE was a competitive inhibitor for CYP2D6. No report presently 
exists regarding the effect of MSE on the mode of inhibition of the CYP enzyme; hence, no 
comparison could be made with the present data. 
Since MSE is a potent CYP3A4 and CYP2D6 inhibitor, co-administration of drugs and herbs that 
are metabolized by the CYP enzymes CYP3A4 and CYP2D6 will have the potential to abolish 
metabolic clearance in vivo, resulting in unwanted toxic effects. Hence, the study of herbs as potential 
drug inhibitors is important for minimizing the unwanted consequences of herb-drug interactions. The 
potential of the extract of M. speciosa to affect drug clearance and deposition may increase if used in 
combination with one or more drugs that are substrates for CYP3A4, CYP2D6 and CYP1A2; with 
other herbs that are known substrates of CYP3A4; and with other isoforms of these CYP enzymes, 
such as St. John’s wort, garlic, gingko, ginseng and grapefruit, which have been reported to have CYP 
inhibition properties [16,22]. Hence these substrates can potentially enhance or inhibit the effects of  
M. speciosa [15]. High doses of M. speciosa extract might be taken by chronic users because of 
tolerance effects. Since MSE showed a potent inhibitory effect on CYP3A4 and CYP2D6, the two 
enzymes involved in the metabolism of most drugs, with IC50 and Ki values lower than 20 µg/mL [14], 
it is necessary for patients and doctors to be aware of potential drug interactions when MSE is  
co-administered with other medications. 
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Figure 4. Chemical structure of mitragynine and morphine. 
 
3. Experimental 
3.1. Chemicals 
Recombinant human CYP3A4, CYP2D6, CYP1A2 and CYP2C19 enzymes; marker substrates  
3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC), 7-benzyloxy-4-
(trifluoromethyl)-coumarin (BFC) and 7-hydroxy-4-(trifluoromethyl)-coumarin (HFC); and reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) regeneration system (NRS) were purchased 
from Gentest Corporation (Woburn, MA, USA), while all the other chemicals and standard references, 
including 3-cyano-7-ethoxycoumarin (CEC), quinidine, ketoconazole, tranyl-cypromine and furafylline, 
were purchased from Sigma Aldrich (St. Louis, MO, USA). 
3.2. Plant Extraction 
Fresh leaves of M. speciosa Korth were collected from the Kangar forest (Perlis State, Malaysia), 
which is close to the national border between Malaysia and Thailand. A methanol-chloroform 
extraction method was used to extract the alkaloids. The leaves (5 kg) were dried and soaked in 4 L 
methanol for three days. The methanol was filtered and the filtrate was evaporated using a rotary 
evaporator. This extraction and evaporation procedure was repeated three times. After that, 1 part of 
crude methanol extract was redissolved in around 35 parts of 1:9 acetic acid-distilled water and then 
washed with an adequate amount of hexane. The acidic layer was made alkaline to pH 9 using 
ammonia hydroxide and extracted with chloroform. The collected organic layer was filtered through 
anhydrous sodium sulphate, and the filtrate was concentrated using a rotary evaporator to obtain 5 g of 
crude alkaloid extract, which was then dissolved in dimethyl sulfoxide (DMSO) and the presence of 
alkaloid was confirmed using the Dragendorff test [23]. 
3.3. Fluorometric Enzyme Inhibition Assays 
3.3.1. Time and Concentration Linearity 
The fluorescence readings of the corresponding metabolites were measured at 10, 20, 30, 45, 60 and 
90 min after adding the NRS solution. Km values that had been established by Crespi et al. were used 
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as the substrate concentrations in this assay [11]. Optimal incubation times were calculated from the 
linearity of the graph.  
3.3.2. Determination of Km and Vmax Values 
Reactions were carried out with 10 different substrate concentrations: 1–200 µM BFC for CYP3A4, 
0.04–100 µM AMMC for CYP2D6, 0.13–100 µM CEC for CYP1A2 and 0.23–300 µM CEC for 
CYP2C19, in three-fold dilutions with respective buffer. The stock concentration was  
20 mM for all the substrates. The previously determined optimal incubation times were used 
throughout the experiment. Km and Vmax values for each of the CYP enzymes were determined by 
using Michealis-Menten plots. The concentration of DMSO did not exceed 0.2% and that of ACN  
did not exceed 2%. DMSO and acetonitrile (ACN) have been known to be potent inhibitors of  
CYP enzymes.  
3.3.3. Half-Maximal Inhibitory Concentration (IC50) Determination of Inhibitors and Plant Extracts  
The assays were performed by using the modified Crespi method [11]. Incubations were conducted 
in a total reaction volume of 150 µL in 96-well FluoroluxTM HB black, flat-bottom microplates from 
Dynex (Chantilly, VA, USA). The final concentrations of the plant extracts (0.05–1000 µg/mL) and 
positive controls (0.005–100 µM) were prepared by using a 3× dilution method. NRS was prepared by 
using 3.3 mM of glucose-6-phosphate (G6P), 0.06 U of glucose-6-phosphate dehydrogenase (G6PDH), 
3.3 mM of MgCl2 and 1.3 mM of nicotinamide adenine dinucleotide phosphate (NADP+). The reaction 
was initiated by addition of NRS (20 µL) into a mixture of pre-warmed enzyme/substrate mix (30 µL), 
test compound (20 µL) and buffer (80 µL), followed by 30 min of incubation at 37 °C. Following that, 
the reactions were terminated by addition of stop solution (75 µL, 4:1 ACN: 0.5 M Tris base). The 
released fluorescence was scanned using a fluorescence plate scanner, VICTORTM X5, Perkin Elmer 
(Waltham, MA, USA), at the optimal wavelength of the metabolite. Positive and negative controls 
were run with every assay. Data were exported and analyzed with PRISM software (version 5.04). IC50 
values were calculated using the relative IC50 determination. The results are presented as the mean of 
three replicates for at least two independent experiments and the protocol is summarized in Table 3. 
Table 3. Summary of the components of the fluorometric enzyme inhibition assays. 
 CYP3A4 CYP1A2 CYP2C19 CYP2D6 
Substrate (final) BFC: 50 µM CEC: 5 µM CEC: 25 µM AMMC: 1.5 µM 
Enzyme 1.0 pmol/well 0.5 pmol/well 0.5 pmol/well 1.5 pmol/well 
Standard inhibitor Ketoconazole Furafylline Tranylcypromine Quinidine 
Phosphate buffer 200 mM  100 mM  50 mM  100 mM  
Fluorescence Filter Ex: 409 nm Ex: 409 nm Ex: 409 nm Ex: 390 nm 
 Em: 530 nm Em: 460 nm Em: 460 nm Em: 460 nm 
Temperature 30 °C 25 °C 30 °C 30 °C 
Incubation time 30 min 20 min 30 min 30 min 
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3.3.4. Determination of Ki Values and Modes Of Inhibition 
The apparent inhibition constant (Ki) values were further determined for concentrations of 
substrates ranging from 3.125 to 100 µM at different concentrations of MSE (0.125–300 µg/mL). 
Lineweaver-Burk plots, Dixon plots and secondary reciprocal plots were plotted to determine the Ki 
values and mode of inhibition. 
4. Conclusions 
The modified Crespi CYP inhibition method used in this study is a relatively fast and  
cost-effective way to perform a CYP inhibition assay. In this study, M. speciosa alkaloid extract 
inhibited CYP enzymes with varying degrees of potency. From the Ki and IC50 values, the results 
showed that MSE is a potent inhibitor of CYP3A4 and CYP2D6 (Ki and IC50 values ≤ 20 µg/mL), 
implying a high potential risk of herb-drug interactions, especially when patients consume large 
amounts of extract. The extract was found to moderately inhibit CYP1A2 (IC50 values 20–100 µg/mL) 
but there was no significant inhibition of CYP2C19 (<50% inhibition at the highest concentration of 
MSE). Competitive inhibition was observed for CYP2D6 and non-competitive inhibition was found 
for the other CYP isoforms. At present, the active constituent responsible for inhibition of the CYPs 
remains unknown. Further work is required to identify the inhibition properties of each of the active 
constituents of M. speciosa extracts. 
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